GSK has posted better-than-expected revenues in 2022, helping to round off a year in which it finally shed its consumer division to create a leaner pharma and vaccines-focused company.
The UK-headquartered company reported full-year sales of £29.3bn ($36.17bn) up by 19% (or +13% at constant exchange rates), and even...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?